@prefix pubblicazioni: . @prefix unitaDiPersonaleInterno: . @prefix prodotto: . unitaDiPersonaleInterno:MATRICOLA8491 pubblicazioni:autoreCNRDi prodotto:ID24133 . @prefix prodottidellaricerca: . @prefix istituto: . istituto:CDS035 prodottidellaricerca:prodotto prodotto:ID24133 . @prefix modulo: . modulo:ID2696 prodottidellaricerca:prodotto prodotto:ID24133 . @prefix rdf: . @prefix retescientifica: . prodotto:ID24133 rdf:type retescientifica:ProdottoDellaRicerca , prodotto:TIPO1101 . @prefix rdfs: . prodotto:ID24133 rdfs:label "Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with NASH (Articolo in rivista)"@en . @prefix xsd: . prodotto:ID24133 pubblicazioni:anno "2009-01-01T00:00:00+01:00"^^xsd:gYear ; pubblicazioni:doi "10.1002/hep.23116"^^xsd:string . @prefix skos: . prodotto:ID24133 skos:altLabel "
Gastaldelli A, Harrison SA, Belfort R, Hardies J, Balas B, Schenker S, Cusi K. (2009)
Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with NASH
in Hepatology (Baltim. Md.); John Wiley & Sons Inc., Hoboken (Stati Uniti d'America)
"^^rdf:HTML ; pubblicazioni:autori "Gastaldelli A, Harrison SA, Belfort R, Hardies J, Balas B, Schenker S, Cusi K."^^xsd:string ; pubblicazioni:paginaInizio "1087"^^xsd:string ; pubblicazioni:paginaFine "1093"^^xsd:string ; pubblicazioni:url "http://www.ncbi.nlm.nih.gov/pubmed/19670459"^^xsd:string ; pubblicazioni:numeroVolume "50"^^xsd:string . @prefix ns11: . prodotto:ID24133 pubblicazioni:rivista ns11:ID426824 ; pubblicazioni:pagineTotali "7"^^xsd:string ; pubblicazioni:numeroFascicolo "4"^^xsd:string ; skos:note "ISI Web of Science (WOS)"^^xsd:string , "PubMe"^^xsd:string ; pubblicazioni:affiliazioni "Diabetes Division, Radiology Department, Research Imaging Center, and\nGastroenterology Division, and the Audie L. Murphy Veterans Administration Medical\nCenter, The University of Texas Health Science Center at San Antonio (UTHSCSA),\nSan Antonio, TX; Fondazione G. Monasterio and Institute of Clinical\nPhysiology, National Research Council, Pisa, Italy; Gastroenterology Division, Brooke\nArmy Medical Center, San Antonio, TX"^^xsd:string ; pubblicazioni:titolo "Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with NASH"^^xsd:string ; prodottidellaricerca:abstract "Pioglitazone treatment improves insulin resistance (IR), glucose metabolism, hepatic steatosis, and necroinflammation in patients with nonalcoholic steatohepatitis (NASH). Because abnormal lipid metabolism/elevated plasma free fatty acids (FFAs) are important to the pathophysiology of NASH, we examined the impact of pioglitazone therapy on adipose tissue insulin resistance (Adipo-IR) during the treatment of patients with NASH. To this end, we assessed glucose/lipid metabolism in 47 patients with impaired glucose tolerance/type 2 diabetes mellitus and NASH and 20 nondiabetic controls. All individuals underwent a 75-g oral glucose tolerance test (OGTT) in which we measured glucose tolerance, IR, and suppression of plasma FFAs. We also measured Adipo-IR index (fasting, FFAs x insulin), hepatic fat by magnetic resonance spectroscopy, and liver histology (liver biopsy). Patients were randomized (double-blind) to diet plus pioglitazone (45 mg/day) or placebo for 6 months, and all measurements were repeated. We found that patients with NASH had severe Adipo-IR and low adiponectin levels. Fasting FFAs were increased and their suppression during the OGTT was impaired. Adipo-IR was strongly associated with hepatic fat (r= 0.54) and reduced glucose clearance both fasting (r=0.34) and during the OGTT (r=0.40, all P <0.002). Pioglitazone significantly improved glucose tolerance and glucose clearance, steatosis and necroinflammation (all P<0.01-0.001 versus placebo). Fasting/postprandial plasma FFAs decreased to levels of controls with pioglitazone (P<0.02 versus placebo). Adipo-IR decreased by 47% and correlated with the reduction of hepatic fat (r=0.46, P=0.009) and with the reduction in hepatic necroinflammation (r=0.47, P=0.0007). CONCLUSION: Patients with NASH have severe Adipo-IR independent of the degree of obesity. Amelioration of Adipo-IR by pioglitazone is closely related to histological improvement and plays an important role during treatment of patients with NASH."@en . @prefix ns12: . prodotto:ID24133 pubblicazioni:editore ns12:ID363 ; prodottidellaricerca:prodottoDi istituto:CDS035 , modulo:ID2696 ; pubblicazioni:autoreCNR unitaDiPersonaleInterno:MATRICOLA8491 . @prefix parolechiave: . prodotto:ID24133 parolechiave:insiemeDiParoleChiave . ns12:ID363 pubblicazioni:editoreDi prodotto:ID24133 . ns11:ID426824 pubblicazioni:rivistaDi prodotto:ID24133 . parolechiave:insiemeDiParoleChiaveDi prodotto:ID24133 .